Expression of MDM2 full length (FL) and alternatively spliced variant MDM2-A was evaluated by immunoblotting in a group of cancer cell lines including GIST cell lines (GIST882, GIST-T1, and GIST430), breast cancer cell lines (SKOV3, OVCA429, and ES2), non-small cell lung cancer cell lines (PC-9 and A549), mesothelioma cell lines (MESO924, MESO428, and JMN1B), and liposarcoma cell lines (LPS510, LPS141, and LPS141/239) (Figure 1). This evidence concerns the gene MDM2 and cancer.